Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

SUNNYVALE, Calif., Feb. 12, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the investigational oral agent ibrutinib monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and to ibrutinib monotherapy for the treatment of patients with Waldenstrom's macroglobulinemia (WM), both of which are B-cell malignancies.

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development."[i]  The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacylics, together with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with MCL and WM. The company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

"This is a historic moment in oncology. We are truly honored to have received this Breakthrough Designation and are pleased for patients and clinicians with the FDA's decision to expedite the development of ibrutinib,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. ... device company, announced today that its new PicoWay® device ... all types and colors and pigmented lesions on any ... wavelength device, with 532nm and 1064nm wavelengths, which utilizes ... skin using pulses which are trillionths of a second, ...
(Date:7/28/2014)... 28, 2014  ResMed (NYSE: RMD ), ... treatment of sleep-disordered breathing and other chronic respiratory conditions, ... against Taiwanese medical device manufacturer APEX Medical ... APEX WiZARD 210 and 220 masks.  The judgment was ... Munich , is appealable, and applies throughout Germany.  ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, ... invited to meet with Linde,s Healthcare division experts ... be held at McCormick Place in Chicago, ... "Hospitals demand nothing less than complete confidence in a ... Linde,s Healthcare Segment manager. "Linde understands the importance of ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Inc. (Pink Sheets: SNDY ) is pleased to ... product line consisting of urology surgical and diagnostic instruments. The ... modifications to current product offerings, and five completely redesigned instruments; ... focus is to strengthen its domestic market share in the ...
... 2011 Colorcon, Inc., today announced the expansion ... to include PVA-based, high-productivity systems designed specifically for ... European Commission Directive (2010/69/EU), already ... existing additives in certain food supplement products.  The ...
Cached Medicine Technology:Solos Endoscopy, Inc. To Introduce New Urology Instrument Line 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... the majority of professionals engaged in the field ... the Transplantation and Immunology Research Network ... and immunology research. As modern organ transplantation continues ... network that could provide more opportunities for physicians, ...
(Date:7/28/2014)... who live near green spaces deliver babies with ... study, "Green Spaces and Adverse Pregnancy Outcomes" published ... . , A team of researchers from Israel ... (BGU), evaluated nearly 40,000 single live births from ... to determine the impact of green surroundings during ...
(Date:7/28/2014)... into improving treatment for patients with one of the ... funding boost. , Chronic obstructive pulmonary disease (COPD) is ... breathing difficulties due to long-term damage to the lungs. ... 10 per cent of all hospital admissions in the ... to hospital after they are discharged. , ...
(Date:7/28/2014)... a test developed at University of Colorado Skaggs School ... Colo (July 28, 2014) An influential new test, ... at the CU School of Pharmacy, helps monitor the ... combination of tenofovir/emtricitabine), which is taken once daily to ... the AIDS 2014 Conference and published in Lancet ...
(Date:7/28/2014)... Malibu, CA (PRWEB) July 28, 2014 ... upon us, it is welcome news that a ... effective than current protection is under development by SunSeeker ... by NASA to protect spacecraft from the extreme heat ... protection to both firefighters and homes. , “Our firefighters ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2
... , ... embrace new technology. , ... MA (PRWEB) January 11, 2010 -- SonRidge, LLC, a catering and chef supplies company located ... for their clients in the food industry. What they discovered was an innovative resolution that ...
... ... and marketer of all-natural sunscreen products launched their website at solaraegis.com. , ... (PRWEB) January 13, 2010 -- ... products launched their website at www.solaraegis.com ., , , , ,"The site ...
... ... and financial security pet health insurance makes sense. Veterinarians once skeptical to the value ... insurance. , ... PA (PRWEB) January 14, 2010 -- Pet Health Insurance in the United States and ...
... ... stresses importance of greater awareness of brain injuries and serious lifelong implications for victims ... San Francisco, ... Year,s Day, in which top-ranked American snowboarder Kevin Pearce suffered a severe brain injury ...
... led by Professor Eduardo Franco, Director of McGill University,s ... colleagues from McGill and Universit de Montral/Centre Hospitalier de ... per cent) of young adults in a new sexual ... nearly half (44 per cent) were infected with an ...
... , , , NEW YORK ... a leading provider of software to public retirement organizations, announced ... System implementation for the State Teachers Retirements System of ... as a replacement to their legacy contributions, pension, disbursement, and ...
Cached Medicine News:Health News:Insulated Transport Containers Go Green 2Health News:SolarAegis, LLC. Website Helps You Have Fun In the Sun, Safely 2Health News:Pet Health Insurance Grows as Pets Live Longer and Healthier Lives 2Health News:Pet Health Insurance Grows as Pets Live Longer and Healthier Lives 3Health News:Pet Health Insurance Grows as Pets Live Longer and Healthier Lives 4Health News:Pet Health Insurance Grows as Pets Live Longer and Healthier Lives 5Health News:Snowboarding Accident Provides Tragic Reminder of Serious Risk of Brain Injuries in Athletic and Occupational Environments 2Health News:McGill-CHUM study: 56 percent of young adults in a new sexual relationship infected with HPV 2Health News:State Teachers Retirement System of Ohio Goes Live on V3 Benefits Administration System 2Health News:State Teachers Retirement System of Ohio Goes Live on V3 Benefits Administration System 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: